ArticlePsychopharmacology2026
From uniform pharmacotherapy to precision psychiatry: reinforcement sensitivity associations with SSRI outcomes.
Article in Psychopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
rationaleSelective serotonin reuptake inhibitors remain the first-line pharmacotherapy for depression and anxiety disorders, yet remission rates are low and variability in treatment outcomes is poorly understood. Reinforcement sensitivity, a trait-based dimension reflecting individual differences in responsiveness to reward and punishment, has been linked to affective vulnerability, but its association with SSRI outcomes has not been systematically examined in humans.
methodsWe conducted an online study recruiting over 3000 participants, of whom 1979 met strict inclusion criteria and were included in the analyses. Participants were taking citalopram, fluoxetine, or sertraline and provided standardized self-report data on anxiety and depressive-like symptoms. In addition, they completed experimental tasks assessing motivation and reinforcement sensitivity. Based on sensitivity to positive and negative reinforcement, participants were classified into four phenotypes (P-N-, P+N+, P-N+, P+N-). Symptom outcomes were analyzed in relation to treatment type, dose, and phenotype.
resultsAcross antidepressant groups, participants exhibited elevated anxiety and depressive-like symptoms relative to controls, consistent with residual symptomatology. Patterns of symptom differences varied across reinforcement sensitivity phenotypes: Lower insomnia levels were observed primarily in P-N- individuals receiving citalopram or fluoxetine, whereas comparable insomnia levels to controls were observed in P+N+ participants receiving sertraline. Genitourinary symptom levels were lower in P-N- and P-N+ phenotypes among citalopram users, and in P+N- individuals receiving fluoxetine or sertraline. Dose-dependent patterns were also observed.
conclusionsWe report exploratory associations between reinforcement sensitivity, residual symptom profiles, and antidepressant treatment characteristics, including SSRI type and dosage. These findings highlight reinforcement sensitivity as a potential descriptive framework for understanding heterogeneity in residual symptoms among SSRI users and underscore the value of large-scale online research.
Indexed as
Identifiers
41999500What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.